While HSP90 inhibitors were often investigated as anti-cancer drugs, we discovered that NVP-BEP800, which acts as an inhibitor of the ATP pocket of HSP90β48, can inhibit LCK in T-ALL and LYN in B-ALL. This evidence concerns the gene HSP90AB1 and cancer.